Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mark

Showing results (961-970 of 1,377) with videos related to

Pageof 138
Sort By:
Glomerular Diseases|August 15, 2024
Effects of Dapagliflozin in Patients with Membranous NephropathyGlenn M Chertow, Hiddo Lambers Heerspink, Patrick B Mark, et al.
Kidney Medicine|April 3, 2024
Cystatin C- and Creatinine-based Estimated GFR Differences: Prevalence and Predictors in the UK BiobankDebbie C Chen, Kaiwei Lu, Rebecca Scherzer, et al.
BJC Reports|November 8, 2024
The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysisBenjamin M P Elyan, Michael K Sullivan, James Hedley, et al.
Annals of Internal Medicine|April 20, 2005
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-IISana M Al-Khatib, Kevin J Anstrom, Eric L Eisenstein, et al.
Hypertension (Dallas, Tex. : 1979)|May 9, 2019
Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular DiseaseC E Welsh, Paul Welsh, Pardeep Jhund, et al.
Circulation|January 11, 2000
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, D B Mark, J E Tcheng, et al.
Journal of the American College of Cardiology|June 1, 1995
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)R A Harrington, A M Lincoff, R M Califf, et al.
Circulation|May 1, 1994
Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplastyD B Mark, C L Nelson, R M Califf, et al.
Nature Nanotechnology|December 13, 2017
Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regressionFengmei Pi, Daniel W Binzel, Tae Jin Lee, et al.
Circulation|November 11, 1991
Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgeryL R Smith, F E Harrell, J S Rankin, et al.
Pageof 138

Showing results (961-970 of 1,377) with videos related to

Sort By:
Pageof 138
Glomerular Diseases|August 15, 2024
Effects of Dapagliflozin in Patients with Membranous NephropathyGlenn M Chertow, Hiddo Lambers Heerspink, Patrick B Mark, et al.
Kidney Medicine|April 3, 2024
Cystatin C- and Creatinine-based Estimated GFR Differences: Prevalence and Predictors in the UK BiobankDebbie C Chen, Kaiwei Lu, Rebecca Scherzer, et al.
BJC Reports|November 8, 2024
The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysisBenjamin M P Elyan, Michael K Sullivan, James Hedley, et al.
Annals of Internal Medicine|April 20, 2005
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-IISana M Al-Khatib, Kevin J Anstrom, Eric L Eisenstein, et al.
Hypertension (Dallas, Tex. : 1979)|May 9, 2019
Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular DiseaseC E Welsh, Paul Welsh, Pardeep Jhund, et al.
Circulation|January 11, 2000
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, D B Mark, J E Tcheng, et al.
Journal of the American College of Cardiology|June 1, 1995
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)R A Harrington, A M Lincoff, R M Califf, et al.
Circulation|May 1, 1994
Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplastyD B Mark, C L Nelson, R M Califf, et al.
Nature Nanotechnology|December 13, 2017
Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regressionFengmei Pi, Daniel W Binzel, Tae Jin Lee, et al.
Circulation|November 11, 1991
Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgeryL R Smith, F E Harrell, J S Rankin, et al.
Pageof 138